Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enrasentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.95 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enrasentan SCHEMBL29356829 | 0.98 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL1031130 | 0.98 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7636324 | 0.98 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8206689 | 0.98 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL1649828 | 0.98 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8008492 | 0.96 | EDNRA (0.97) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7660593 | 0.95 | EDNRA (0.95) | EDNRAEDNRB | |
| SCHEMBL13038489 | 0.94 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL8203979 | 0.94 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL7538909 | 0.94 | EDNRA (0.92) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6114463-A | Copolymers based on vinyl units and their use in electroluminescent devices | BAYER AG (DE) | 2000-09-05 | — | — | US | claimed |
| US-6441173-B1 | NOVEL INTERMEDIATES OF AND CONVERSION TO 3-(2-(2-HYDROXYETH-1-YLOXY) OR (2-CARBOXYMETHOXY)-4-METHOXYPHENYL)-1-(3,4-METHYLENE DIOXYPHENYL)-5-(PROP-1-YLOXY)INDANE-2-CARBOXYLIC ACID | SMITHKLINE BEECHAM CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020087011-A1 | Process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives | SMITHKLINE BEECHAM CORPORATION | 2002-07-04 | — | — | US | disclosed |
| US-6143907-A | 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020087011-A1 | Process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives | CYP1B1, DHPS, IDO1 | EDNRA 1066/4885EDNRB 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.